Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19

Nat Commun. 2024 Oct 17;15(1):8941. doi: 10.1038/s41467-024-53356-5.

Abstract

Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.

MeSH terms

  • Adult
  • Aged
  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • Epitope Mapping
  • Epitopes / immunology
  • Female
  • Health Personnel
  • Humans
  • Male
  • Middle Aged
  • Molecular Mimicry / immunology
  • SARS-CoV-2* / immunology
  • Severity of Illness Index
  • Spike Glycoprotein, Coronavirus / immunology

Substances

  • Autoantibodies
  • Spike Glycoprotein, Coronavirus
  • Epitopes
  • spike protein, SARS-CoV-2